This clinical trial is investigating the efficacy and safety of adjuvant atezolizumab (Tecentriq) or placebo and trastuzumab emtansine (Kadcyla) for HER2-positive breast cancer at high risk of recurrence following preoperative therapy.
Who is the trial for? Women or men with confirmed HER2-positive invasive breast cancer who have completed preoperative preoperative chemotherapy and HER2-directed therapy, including trastuzumab followed by surgery, with a finding of residual invasive disease in the breast and/or axillary lymph nodes. Of note, there must be an interval of no more than 12 weeks between the date of primary surgery and the date of randomization. They should have no serious medical conditions and a life expectancy of greater than six months. Auckland City Hospital and Tauranga Hospital are the New Zealand sites for this trial, although recruitment is now closed at Tauranga (April 2024).
View this link for full trial information.
Please consult with your doctor or medical team if you are interested in participating in this trial.
29 April 2024
